ICPT
NASDAQIntercept Pharmaceuticals Inc.
Latest news
25 items- PRIntercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 ConferenceMORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024. The conference will be held from May 18-21 in Washington, D.C. "We are pleased to participate in this year's DDW and share our latest findings, including new data from our Phase 2 trial evaluating a fixed-dose combination of obeticholic acid and bezafibrate in patients with PBC," said Sangeeta Sawh
- PRIntercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBCsNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registriesFDA has assigned a PDUFA target action date of October 15, 2024 MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supple
- NEWSCymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: AnalystMonday, Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for primary biliary cholangitis (PBC), including pruritus, complements Gilead’s existing liver portfolio. Baird writes that Gilead’s investment in seladelpar for liver disease appears to be a strategically sound move, especially compared to potential investments in oncology. The company’s focus on a space where it has demonstrated commercial success is seen as a positive step to restore confidence in its growth prospects. Despite the m
- SECSEC Form 15-12G filed by Intercept Pharmaceuticals Inc.15-12G - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)
- SECSEC Form EFFECT filed by Intercept Pharmaceuticals Inc.EFFECT - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)
- SECSEC Form EFFECT filed by Intercept Pharmaceuticals Inc.EFFECT - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)
- SECSEC Form EFFECT filed by Intercept Pharmaceuticals Inc.EFFECT - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)
- INSIDERAkkaraju Srinivas returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERFundaro Paolo returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERVenezia Rocco returned $278,711 worth of shares to the company (14,669 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERBerrey M Michelle returned $984,010 worth of shares to the company (51,790 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERRichardson Linda M returned $505,115 worth of shares to the company (26,585 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERBenatti Luca returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERSblendorio Glenn returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERMiller-Rich Nancy returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERSantini Gino returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERRosa-Bjorkeson Dagmar returned $220,875 worth of shares to the company (11,625 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERGottesdiener Keith Michael returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERFord David A returned $406,600 worth of shares to the company (21,400 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERFreedberg Jared returned $641,478 worth of shares to the company (33,762 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERBradbury Daniel returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERDurso Jerome Benedict returned $1,953,675 worth of shares to the company (102,825 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERPruzanski Mark closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- INSIDERSaik Andrew returned $859,636 worth of shares to the company (45,244 units at $19.00), closing all direct ownership in the company (SEC Form 4)4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)
- NEWSIntercept Announces New Phase 2 Data Showing Significant Impact Of OCA-Bezafibrate Combination On Normalization Of Multiple Key Biomarkers Of PBC-Induced Liver Damage At AASLD The Liver Meeting 2023Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% reduction from baseline in serum ALP (primary endpoint)Treatment-emergent adverse events were generally balanced across all cohorts in both studiesData support progression to Phase 3 trials of sustained release formulation of bezafibrate with low doses of OCAResults featured in late-breaking poster presentation on Monday, November 13, during The Liver Meeting® 2023MORRISTOWN, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE)
ICPT FAQ
7 questionsWhat does Intercept Pharmaceuticals Inc. do?
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical...Where does ICPT stock trade?
Intercept Pharmaceuticals Inc. (ICPT) is listed on NASDAQ.What sector and industry is ICPT in?
Intercept Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Intercept Pharmaceuticals Inc. go public?
Intercept Pharmaceuticals Inc. (ICPT) completed its IPO in 2012.What are analysts saying about ICPT?
Intercept Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1900.00 price target on 2023-07-13. Recent price targets range from $800.00 to $2900.00.What companies are similar to ICPT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ICPT side-by-side with any of them on Quantisnow.How can I track ICPT on Quantisnow?
Quantisnow aggregates Intercept Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ICPT to receive live email and push alerts on every new disclosure.